Abliva
0.134
SEK
+1.36 %
ABLI
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Be the first to follow this company
+1.36%
-13.42%
-31.53%
-30.47%
-45.34%
-46.32%
-75.8%
-89.23%
-97.01%
abliva.com/sv/investerare
Abliva is a pharmaceutical company. The company develops drugs for the treatment of primary mitochondrial diseases. These congenital, rare and often very serious diseases occur when the cell's energy supply, the mitochondria, does not function properly. The portfolio includes projects in various stages and ranges from the early detection phase to the clinical phase. The company was previously known as NeuroVive Pharmaceutical.
Revenue
140K
EBIT %
-68,964.29 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
ABLI
Daily low / high price
0.126 / 0.135
SEK
Market cap
216.31M SEK
Turnover
227.5K SEK
Volume
1.8M
Financial calendar
Interim report
2024-11-21
Annual report
2025-02-21
Interim report
2025-05-22
Interim report
2025-08-22
Interim report
2025-11-21
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Hadean Capital I AS | 22.4 % | 22.4 % |
| Oslo Pensjonsforsikring AS | 14.9 % | 14.9 % |
| IP Group Plc | 8.1 % | 8.1 % |
| Försäkringsaktiebolaget, Avanza Pension | 3.3 % | 3.3 % |
| Christen Sveaas | 2.7 % | 2.7 % |
| MP Pensjon PK | 2.7 % | 2.7 % |
| Kistefos AS | 2.1 % | 2.1 % |
| Liljenberg, Stefan | 1.5 % | 1.5 % |
| Nordnet Pension insurance | 1.1 % | 1.1 % |
| Johan Thorell | 0.8 % | 0.8 % |
| Gunvald Berger | 0.6 % | 0.6 % |
| Swedbank Insurance | 0.6 % | 0.6 % |
| Johan Bard | 0.6 % | 0.6 % |
ShowingAll content types
Abliva presenterar på BioStock Life Science Summit 21 november
BioStock: Abliva leads the fight against mitochondrial disease
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools